- Home
- CANF vs SEED Comparison
CANF vs SEED Comparison
Compare CANF & SEED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- SEED
- Stock Information
- Founded
- CANF 1994
- SEED 1997
- Country
- CANF Israel
- SEED China
- Employees
- CANF N/A
- SEED N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- SEED Farming/Seeds/Milling
- Sector
- CANF Health Care
- SEED Consumer Staples
- Exchange
- CANF Nasdaq
- SEED Nasdaq
- Market Cap
- CANF 14.4M
- SEED 14.5M
- IPO Year
- CANF N/A
- SEED N/A
- Fundamental
- Price
- CANF $2.01
- SEED $2.30
- Analyst Decision
- CANF Strong Buy
- SEED
- Analyst Count
- CANF 2
- SEED 0
- Target Price
- CANF $14.00
- SEED N/A
- AVG Volume (30 Days)
- CANF 63.2K
- SEED 19.8K
- Earning Date
- CANF 11-26-2024
- SEED 11-29-2024
- Dividend Yield
- CANF N/A
- SEED N/A
- EPS Growth
- CANF N/A
- SEED N/A
- EPS
- CANF N/A
- SEED 1.21
- Revenue
- CANF $667,000.00
- SEED $16,516,031.00
- Revenue This Year
- CANF $409.56
- SEED N/A
- Revenue Next Year
- CANF N/A
- SEED N/A
- P/E Ratio
- CANF N/A
- SEED $2.04
- Revenue Growth
- CANF N/A
- SEED 64.93
- 52 Week Low
- CANF $1.87
- SEED $1.37
- 52 Week High
- CANF $4.69
- SEED $6.38
- Technical
- Relative Strength Index (RSI)
- CANF 38.15
- SEED 39.60
- Support Level
- CANF $1.93
- SEED $2.21
- Resistance Level
- CANF $2.21
- SEED $2.50
- Average True Range (ATR)
- CANF 0.20
- SEED 0.22
- MACD
- CANF -0.02
- SEED -0.01
- Stochastic Oscillator
- CANF 15.52
- SEED 34.83
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company. In crop seed biotechnologies, the company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.